Stockreport

CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK [Yahoo! Finance]

CureVac N.V. - Ordinary Shares  (CVAC) 
PDF For influenza A strains, geometric mean titers numerically exceeded those elicited by the licensed comparator vaccines consistently across all tested dose levels and ag [Read more]